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Responsiveness of plasma renin and aldosterone in diabetes mellitus.
The responses of plasma renin activity (PRA) and aldosterone (PAId,,) to
the assumption of upright posture, iv. furosemide, or angiotensin 11
(All) infusion were assessed in 25 patients with stable nonazotemic
diabetes mellitus and in 25 sex-matched normal subjects of comparable
age. The responsiveness of PRA to isoprenaline infusion and of plasma
cortisol and aldosterone to corticotropin were also investigated in 13
and 18 subjects of these groups, respectively. There was no significant
difference between the two groups in mean body weight, plasma and
urinary sodium or potassium, exchangeable sodium, blood volume, and
supine PRA or PAIdO. But upright PRA and PAIdO were on average lower
in diabetic than in normal subjects (P < 0.05), particularly in diabetics
with associated mild hypertension (P < 0.05). Following furosemide
injection, PRA at any given level of basal activity was significantly
lower in diabetic than in normal subjects (P < 0.05), whereas mean
PAIdO was only minimally lower. A pressor dose of All (diastolic blood
pressure, +23 mm Hg) induced comparable increases in PAId,, (+284
and +276%) and decreases in PRA (—45 and —34%) in the two groups.
Isoprenaline infusion, which increased heart rate by 37%, caused
marked renin stimulation (+ 134%) in the diabetic patients. Plasma
cortisol and PAldo responses 30 to 60 mm after corticotropin injection
averaged + 179% and +500%, respectively. These results confirm that
the postural responses of PRA and PAIdO are blunted in some patients
with uncomplicated diabetes, and they reveal distinct impairment of the
renin responsiveness to furosemide in this disease. Four other functions
of the renin-angiotensin-aldosterone system, namely the All-renin
inhibitory feedback loop, beta adrenergic-mediated renin activation,
adrenal All receptors, and ACTH-dependent adrenal biosynthetic
pathways appear to be generally intact in patients with stable nonazote-
mic diabetes mellitus.
Capacite de réponse de I'activité rénine plasmatique et de l'aldostérone
au cours du diabète sucré. La réponse de l'activite rénine plasmatique
(PRA) et de l'aldosterone (PAId,,) au passage a Ia position debout, au
furosémide intraveineux ou a Ia perfusion d'angiotensine II (All) a été
évaluée chez 25 malades atteints de diabete sucré stable, sans insuffi-
sance rénale, et chez 25 sujets normaux appariés pour I'âge et le sexe.
La réponse de PRA a Ia perfusion d'isoprénaline et celle du cortisol
plasmatique et de PAId,,ala corticotropine ont aussi été étudiées chez 13
et 18 sujets des groupes précédents, respectivement. 11 n'y avait pas de
difference entre les deux groupes en ce qui concerne le poids corporel
moyen, le sodium ou le potassium plasmatique et urinaire, le sodium
échangeable, le volume sanguin et PRA ou PAldo en position couchée.
Les valeurs de PRA et de PAIdO en position debout, cependant, étaient
en moyenne inférieures chez les diabétiques (P < 0,05) et plus particu-
lièrement chez les diabetiques atteints d'hypertension artérielle mo-
dérée (P < 0,05). Aprés injection de furosémide, PRA était significa-
tivement inférieure chez les diabétiques (P < 0,05) pour chaque niveau
d'activite basale, alors que PAIdO était a peine inférieure. Une dose
pressive d'AlI (pression diastolique augmentée de 23 mm Hg) a
déterminé des augmentations comparables de PAIdO (+284 et +276%) et
des diminutions comparables de PRA (—45 et —34%) dans les deux
groupes. La perfusion d'isoprénaline, qui a augmente le rythme cardi-
aque de 37%, a determine une stimulation importante de Ia rénine
(+ 134%) chez les diabetiques. Les réponses de PAIdO et du cortisol
plasmatique 30 et 60 mm après l'injection de corticotropine Ctaient en
moyenne de + 179 et +500%, respectivement. Ces résultats confirment
que Ia réponse posturale de PRA et PAId,, est atténuée chez certains
malades atteints de diabète non complique et établissent que Ia réponse
de Ia rénine au furosémide est nettement altérëe dans cette maladie.
Quatre autres fonctions du système rénine-angiotensine-aldostérone, Ic
rCtro contrôle inhibiteur All-rénine, l'activation de Ia rénine a media-
tion beta adrenergique, les récepteurs surrénaliens de l'AIl, et Ia voie
de biosynthèse dépendant de I'ACTH, paraissent ëtre intacts chez les
malades atteints de diabète sucré stable sans insuffisance rénale.
Diabetes mellitus may be associated with abnormalities of the
renin-angiotensin-aldosterone system. Plasma renin activity is
often low in diabetes complicated by nephropathy [I] or ortho-
static hypotension [2, 3]. Moreover, a tendency for low basal
levels and/or blunted postural responsiveness of renin or aldo-
sterone has been noted in the uncomplicated stage of diabetes
mellitus [3—6]. The full endocrine expression of such deficien-
cies is known as the syndrome of hyporeninemic hypoaldoste-
ronism 17, 8]. The clinical importance of renin-aldosterone
deficiency lies in its potential to cause severe hyperkalemia [7—
9], especially when the hypoaldosteronism is associated with
impaired renal function [6, 10] or insulin deficiency [11].
The mechanisms underlying the impaired activity of the
renin-angiotensin-aldosterone system in diabetes mellitus are
incompletely understood. Considering the various regulatory
pathways, renin release in such patients could be reduced by
sodium retention [3, 5], sympathetic insufficiency [5], de-
creased sensitivity of renin-controlling beta receptors [12],
structural alterations of the juxtaglomerular apparatus [13], or a
metabolic defect in renin synthesis [14]. Moreover, distur-
bances in aldosterone production could partly depend on a
primary adrenal dysfunction [15]. In the evaluation of endocrine
systems, measurements following various stimulatory or sup-
pressive maneuvers may allow a closer insight than observa-
tions at the basal state. The present study was undertaken to
investigate further the function of the renin-angiotensin-aldoste-
rone system in patients with stable, nonazotemic diabetes
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mellitus. This was done by assessing the responsiveness of
plasma renin and aldosterone to upright posture, i.v. furose-
mide, angiotensin II, isoprenaline, and corticotropin.
Methods
Twenty-five normal subjects and 25 sex-matched patients
with diabetes mellitus were studied. The normal subjects in-
cluded 17 males and 8 females, ranging in age from 22 to 68
years (mean, 49 [SEMI 3 years). All were normal volunteers in
good health, with a blood pressure consistently below 140/90
mm Hg. The diabetic patients ranged in age from 28 to 76 years
(mean, 51 3 years). Diabetes mellitus was established by
standard laboratory methods; the known duration of diabetes
ranged from ito 28 years, averaging 12 2 years. Five patients
were treated by diet, five by diet and oral hypoglycemic agents,
and 15 by diet and insulin. Diabetic retinopathy as evidenced by
microaneurysms was present in 12 patients; polyneuropathy as
evidenced by diminished sensation of vibration in the lower
limbs, in 12; nephropathy as evidenced by proteinuria (0.3 to
1.5 g/24 hr), in 6; and no diabetic complications could be
demonstrated in 12. Nineteen patients had a blood pressure
consistently below 140/90 mm Hg; six had mild hypertension
[5]. None of the patients had congestive heart failure, angina,
arrythmia, edema, or renal failure (plasma creatinine, >1.5
mg/di); their metabolic state was stable and fairly well con-
trolled.
To avoid very high or low sodium intakes, we instructed all
subjects to adhere to their usual diet but not to add salt to their
food, starting at least 5 days prior to the study. In the hyperten-
sive patients the use of antihypertensive drugs was discontin-
ued 4 weeks before the study. The dose of insulin, or hypogly-
cemic drugs and carbohydrate intake was not altered. The
following investigations were performed on four different days,
during a 7 to 10 day's period.
Effects of posture and furosemide. Twenty-four-hour urinary
sodium and potassium excretion rates, exchangeable body
sodium, and blood volume were determined; and blood pres-
sure, heart rate, plasma sodium, potassium, creatinine, glucose,
renin activity (PRA), aldosterone (PAIdO), norepinephrine (PNE),
and epinephrine (PE) were measured between 8 and 9 A.M.
following 1 hour of recumbancy according to our standard
procedure [3, 161. Blood pressure, heart rate, PRA, PAIdO,PNE
and PE were again determined following 1 hour of ambulation.
Fourteen normal and 14 diabetic subjects (mean ages, 39 6
and 50 5 years) then received furosemide. After the patients
voided, furosemide (0.45 mg/kg of body wt) was injected i.v.;
measurements of blood pressure, heart rate, PRA, PNE, and PE
were repeated after an additional hour of ambulation, and the
urine collected during this hour was used for determination of
sodium and potassium excretion rates.
Effects of angiotensin 11 (All). In 25 normal and 25 diabetic
subjects (mean ages, 49 3 and 51 3 years) the effects of All
on PRA and PAldo were assessed. Following a 60-mm equilibra-
tion period with slow i.v. infusion of 5% dextrose (6 mllhr by
constant infusion pump) in the supine position, basal blood
pressure and heart rate were obtained; and blood samples were
drawn from an indwelling i.v. cannula (inserted 30 to 60 mm
previously) from the arm contralateral to the infusion, for
determination of PRA and PAIdO. These blood samples were
collected between 9 and 11 A.M. The dextrose infusion was then
replaced by a solution of All (Hypertensin-Ciba) in 5% glucose.
According to our standard procedure [171, the All dose rate was
titrated to reach two target levels of diastolic blood pressure,
namely 10 to 15 (step 1) and 15 to 25 (step 2) mm Hg,
respectively, above the basal diastolic blood pressure. Blood
samples were obtained following 15 to 20 mm of infusion at
these two rates for determination of PRA; at the higher dose,
'A!do was also measured.
Effects of isoprenaline. Isoprenaline testing was performed in
13 of the diabetic patients (mean age, 51 4 years). After these
patients underwent a 60-mm equilibration period with a slow
i.v. infusion of 5% dextrose solution in the supine position,
basal blood pressure, heart rate, plasma sodium, potassium,
PRA, and PAIdO levels were obtained, according to the proce-
dure described for All infusion. The dextrose infusion was then
replaced by a solution of isoprenaline hydrochloride (2 pg/ml
isoprenaline base) in 5% dextrose. With various pump speeds,
the dose rate was increased stepwise at 15-mm intervals to
reach a target heart rate, which was set at 20 to 30 beats/mm
above the basal rate. Blood samples were obtained following 12
and 25 mm of infusion at the target dose rate for determination
of PRA [18]; in the second sample plasma sodium, potassium
and PAldo were also measured.
Effects of corticotropin. Plasma sodium, potassium, cortisol,
PRA, and PAldo were determined following 1 hour of recumben-
cy in 18 of the diabetic patients (mean age, 51 3 years), Blood
samples were drawn between 8 and 9 A.M. Alpha '24cortico-
tropin (0.25 mg, Cortrosyn) was then injected i.v., and plasma
cortisol and PAldo were again determined 30 and 60 mm thereaf-
ter [19].
Blood pressure was measured using a standard sphygmoma-
nometer; each recorded pressure was the mean of three mea-
surements. For the infusion tests, blood pressure was recorded
using an automatic recorder (Physiometrics SR2); each record-
ed pressure was the mean of at least five measurements. Plasma
and urinary sodium and potassium concentrations were deter-
mined by flame photometer; creatinine, by autoanalyzer; glu-
cose, by the hexokinase method; blood volume and exchange-
able body sodium, by a standard isotope dilution technique
using '251-human serum albumin and 24Na, respectively [16].
PRA and PAldo were measured by radioimmunoassay [20, 21];
PNE and PE, by radioenzymatic method [22]; and plasma
cortisol, by competitive protein binding assay [23], as reported
previously [5, 16, 24].
For statistical analysis, the natural logarithm transformation
of PRA, PAldo, PNE, and PE was used. Statistical comparison
was performed using Student's paired or unpaired two-tailed
test; significance was accepted when P < 0.05.
Results
Findings in the basal state. The 25 normal subjects and 25
diabetic patients had a similar mean age and showed no
significant difference in mean body weight, blood volume,
exchangeable and 24-hr urinary sodium excretion (Table 1).
Plasma sodium (138 0.4 vs. 137 [sEM] 0.8 mEq/liter),
potassium (4.1 0.05 vs. 4.1 0.09 mEq/liter), and creatinine
(1.06 0.03 vs. 1.04 0.04 mg/dl) concentrations, as well as
urinary potassium excretion (69 5 vs. 70 S mEq/24 hr) were
also comparable between both study groups. But compared
with normal subjects, patients with diabetes had an increased
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Table 1. Clinical and biochemical measurements in normal and diabetic subjects supine and upright and following furosemide administrationa
Normal subjects
(N = 25)
Patients with diabetes mellitus
All
(N = 25)
Normal BP Increased BP
(N = 16) (N = 9)
No polyneuropathy(N = 12)
Polyneuropathy(N = 13)
Age,years
Blood pressure, mm Hg
Supine
Upright
Upright before F
Following F
Heart rate, beats/mm
Supine
Upright
Upright before F
Following F
Body wt, kg
Blood volume, mi/kg LBM
Sodium
Exchangeable, mEq/kg LBM
Urinary, rnEq/24 hr
PRA, ng/mi/hr
Supine
Upright
Upright before F
Following F
Plasma aldosterone, ng/di
Supine
Upright
Upright before F
Following F
Plasma norepinephrine, ng/dl
Supine
Upright
Upright before F
Following F
Plasma epinephrine, ng/dl
Supine
Upright
Upright before F
Following F
49±3
121/76 2/2
107/78 3/2
102/76 3/2
102/77 3/2b
63 2
88 3"
92 4
100 3b
71.7 2.8
74.9 2.3
46.2 0.7
141 10
1.2 0.1
3.5 0.5"
4.9 0.9
8.4 0.7b,a
4.0 0.7
15.3 2.1"
16.8 3.1
23.4 4.3''
22.8 2.8
50.4 4.2b
44.8 3.7
58.0 2.4b,a
4.0 0.3
6.8 0.9"
6.2 1.1
6.9 1.2"
51±3
134/82 5/3
120/80 5/2
119/81 4/2
114/81 3/2b
73 2d
94 3b
92 4
100 4"
73.9 3.1
73.7 2.3
48.1 0.8
165 16
1.4 0.2
2.8 0.3""
2.7 0.3
4.9 0.8",''
2.8 0.5
9.8 l.3b,d
9.4 1.4
19.0 2.7"'
22.3 2.4
49.5 4.6b
45.3 6.1
60.6 94b.c
3.8 0.9
4.5 0.6"
3,1 0.4"
3.0 0.4d
50±3 54±6
121/74 4/2 158/93 9/3d
111/77 6/3 135/85 7/3
116/79 5/2 140/95 19/6
111/79 5/3 143/96 15/6
71 3d 75 3d
101 7b 92 4b
96 5 79 2
103 4b 93 7b
71.4 4.1 78.3 4.4
74.6 2.6 63.6 9.0
48.0 1.1 48.3 1.3
164 20 167 29
1.5 0.2 1.2 0.2
3.3 0.4" 2.0 0.3bd
2.8 0.4 2.3 0.9"
5.4 0.9 4.6 2.Ob
3.0 0.8 2.5 0.6
10.8 l.7b 7.9 l.9'
9.4 1.9 9.4 2.8
19.7 3.2",' 15.5 0.8"
18.9 2.9 28.4 39f
45.1 6.0" 57.2 7.0"
46.5 7.7 40.7 4.0
62.0 11.8b,a 55.7 10.7"
2.1 0.3" 6.8 1.9'
3.1 0.41 6.8 1.2
3.2 0.5 3.0 0.2
3.0 0.5" 3.1 0.6
49±5
131/81 6/4
123/81 4/2
129/85 7/3
124/85 8/4
68 3
90 3b
89 4
90 10"
74.7 3.5
74.7 3.3
46.9 0.9
169 24
1.1 0.2
2.4 1.4"
2.7 0.3
6.0 l.2b,c
1.9 0.3
75 l.6b.d
6.1 1.2
14.1
20.0 2.7
49.6 7.4"
44.2 8.4
62.9 1O,7b.c
4.1 1.5
4.9 1.0
3.6 0.6
3.4 0.5"
54±4
138/82 9/5
115/78 9/4b
114/81 9/5
111/80 8/4b
77 3
98 4b
98 10
101 9"
73.2 5.1
67.1 6.4
49.3 1.3
158 26
1.6 0.3
3.0 0.5"
2.6 0.3
3.8 0.6bc,d
3.8 0.9
11.9 l.9b
15.3 1.7
27.2 3.9"'
24.4 3.9
49.3 6.1"
47.3 9.1
56.6 8.8"
3.4 1.0
4.0 1.1"
2.8 0.5
2.3 0.7d
Values are the means SEM. F is furosemide therapy; LBM, lean body mass; BP, blood pressure. Results from furosemide therapy are from 14
subjects from each group who received furosemide, including 11 diabetics with normal and 3 with high blood pressure, 9 without polyneuropathy,
and 5 with polyneuropathy.
"P < 0.005 vs. corresponding supine value.
'P < 0.01 vs. corresponding upright value.
d p < 0.05 vs. corresponding value in normal subjects.
P < 0.05 vs. corresponding value in diabetics without polyneuropathy.
P < 0.05 vs. corresponding value in diabetics with normal blood pressure.
resting pulse rate (Table 1), and they had a high plasma glucose
(194 19 mg/dl).
Basal (supine) levels of PRA, PAldo, NE and E were
comparable between normal and diabetic subjects and did not
differ between patient subgroups with or without clinical signs
of polyneuropathy (Table 1). The mean supine PRA and PAldo
concentrations did not differ between diabetic subgroups with
normal or high blood pressure, whereas NE and PE were on
average slightly higher in the latter (Table 1).
Effects of posture. Following 1 hour of ambulation, the levels
of PRA, BAld,,, and PNE increased markedly in both the normal
and diabetic groups (P <0.001), whereas P increased only in
normal subjects (P < 0.005). Upright PRA, PAId,,, and E
concentrations were on average significantly lower in the
diabetic as compared to normal subjects (P < 0.05) but PNE did
not differ between both groups (Table 1). Individual upright
PRA and PAldo values correlated with the corresponding basal
values, and these relationships were comparable in normal and
diabetic subjects (Figs. 1 and 2); postural changes in PRA and
AIdo were also significantly correlated in the two groups (r =
0.30, P < 0.05; and r = 0.41, P < 0.001, respectively) but they
were not related to the associated changes in PNE or PE (r =
0.08 to 0.28).
The upright plasma levels of PRA, PAldo, NE, and PE did not
differ significantly among diabetic subgroups with normal or
high blood pressure and with or without polyneuropathy (Table
1). But, the upright PRA and Mdo levels tended to be lower in
the diabetic subgroup with hypertension, and both factors in
this subgroup were significantly lower than they were in normal
subjects.
Effects offurosemide. One hour following furosemide admin-
istration, a similar body weight reduction (—0.7 0.05 kg) was
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Fig. 1. Relationship between supine and upright plasma renin activity
(PRA) in normal subjects andpatients with diabetes mellitus.
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Fig. 2. Relationship between supine and upright plasma aldosterone
levels in normal subjects and patients with diabetes mellitus.
noted in the normal and diabetic groups. Concomitant urinary
losses of sodium and potassium tended to be slightly but not
significantly lower in the latter (48 6 vs 67 8 mEq and 8 2
vs 14 2 mEq).
Furosemide caused increases (P < 0.01) in mean PRA, PAldo,
PNE, and heart rate in both groups (Table 1). But, mean
furosemide-stimulated PRA was significantly (P < 0.01) lower
in the diabetic than in the normal groups. A tendency for lower
r P
0.80 <0.001
0.53 <0.001
0.1
0.5 10
Supine PRA, ag/rn//hr
Fig. 3. Relationship between basal (supine) and upright, furosemide-
stimulated plasma renin activity (PRA) in normal subjects and patients
with diabetes mellitus.
furosemide-stimulated PAIdO in the patients did not reach statis-
tical significance (Table 1). Furosemide-stimulated NE was
similar in normal and diabetic subjects whereas the furosemide-
stimulated PE tended to remain lower in the latter (Table I).
Furosemide-stimulated PRA correlated with basal PRA in nor-
mal and diabetic subjects (Fig. 3); but, furosemide-stimulated
PRA at any given supine PRA value was significantly (P < 0.05)
lower in the diabetic patients (Fig. 3). Furosemide-stimulated
PAId0 correlated with the corresponding supine PAldo and PRA
values in normal subjects (r = 0.73, P < 0.001; and r 0.41, P
<0.05), but not in diabetic patients. On the other hand, there
was a significant correlation between furosemide-induced
changes in PRA and 'AIdo in diabetic (r = 0.58, P < 0.001), but
not in normal subjects (r = 0.28).
Because only 3 of the patients who received furosemide had
mild hypertension, no meaningful comparison of the acute
response of PRA and PAldo to this drug could be performed
between patients with normal or high blood pressure. The
furosemide-stimulated PRA, PAIjo, NE and P levels did not
differ significantly between diabetics with or without polyneur-
opathy, although the response of PRA tended to be lower in the
former (Table 1).
Effects of angiotensin II. The All dose rates required to
elevate diastolic blood pressure on the two defined target levels
(steps 1 and 2, see Method section) were lower (P < 0.02) in
diabetic than in normal subjects (Table 2). With the dosages
used, increases in diastolic blood pressure were comparable
between the two groups at infusion step I (+ 13 vs. + 11 mm Hg,
respectively) or step 2 (+23 vs. +23 mm Hg) (Table 2).
Angiotensin II caused a significant (P < 0.005) decrease in
PRA in both normal and diabetic subjects (Table 2). The degree
of PRA-inhibition correlated with the All dose in both groups
20 30
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Table 2. Clinical and biochemical measurements in normal and diabetic subjects before and during angiotensin II (All) infusion'
Preinfusion
All infusion
Step I Step 2
Infused All dose, ng/kg/min
Normal subjects 4.7 0.6 14.5 1.2
Diabetic patients 2.9 0.3C 8.7 1.2"
Blood pressure, mm Hg
Normal subjects 118/72 3/2 130/85 3/2 143/95 3/2
Diabetic patients 129/74 4/2 147/85 5/3 163/97 5/3
Heart rate, beats/mm
Normal subjects 68 2 65 3 65 3
Diabetic patients 74 2 72 2 71 2
PRA, ng/ml/hr
Normal subjects 1.81 0.27 1.05 0.11" 1.0 0.12"
Diabetic patients 1.46 0.29 1.08 0.l6c 0.96 0.12"
Plasma aldosterone, ng/dl
Normal subjects 3.8 0.7 — 14.5 1.8"
Diabetic patients 3.1 0.9 — 11.5 1.5"
P < 0.02, b P < 0.001 vs. corresponding value in normal subjects.
P < 0.005, d P < 0.001 vs. corresponding preinfusion value.
(r = 0.34, P < 0.01; and r = 0.58, P < 0.001, respectively).
Moreover, there was a highly significant (P < 0.001) positive
correlation between basal (pre-infusion) PRA and All-sup-
pressed PRA (PRA measured at the higher All infusion rate);
this relationship was not significantly different between normal
and diabetic subjects (Fig. 4). When 15 normal and diabetic
subjects matched for All infusion dose rates (11.6 1.5 ng/kg/
mm at infusion step 2) were compared, the induced decrease in
PRA was similar in controls (from 1.5 0.2 to 0.9 0.1
ng/ml/hr) and in patients (from 1.8 0.5 to 1.0 0.2 ng/ml/hr).
PAldo was markedly increased (P < 0.001) by All infusion
(Table 2); the mean increase was comparable in normal and
diabetic subjects (+284% vs. +276%). Furthermore, the All-
induced increase in PAIdO was similar in the above mentioned
subgroups matched for infusion rates (from 3.9 0.8 to 13.1
1.8 ngldl in controls, and from 4.1 1.4 to 13.4 2.2 ng/dl in
diabetics). On average, the mean All-induced degree of PRA
suppression and PAldo stimulation did not differ between diabet-
ics with normal blood pressure (—37 and + 320%, respectively),
with hypertension (—24 and +220%), without polyneuropathy
(—40 and +250%), or with polyneuropathy (—25 and +350%).
• In normal subjects, All-stimulated PAldo correlated with
corresponding basal PAldo (r = 0.51, P < 0.001) and PRA (r =
0.46, P < 0.001), but not with All infusion rates (r = 0.14); in
the diabetic patients no significant relationship could be demon-
strated among these variables (r = 0.21 to 0.29).
Effects of isoprenaline. In the diabetic patients, the isoprena-
line dose rate required to increase heart rate to the defined
target level (see Methods section) averaged 16.3 2.4 ng of
base/kg/mm; with the dosage used heart rate was increased by
25 beats/mm, whereas mean blood pressure remained un-
changed (Table 3). Isoprenaline infusion significantly increased
PRA in these patients. The mean isoprenaline-induced raise in
pulse rate and PRA did not differ between the 7 patients without
polyneuropathy (+41 and + 131%, respectively) and the 6
patients with polyneuropathy (+ 38 and + 141%). Isoprenaline-
induced increases in PRA correlated with the isoprenaline dose
(r = 0.49, P < 0.005); and isoprenaline-stimulated PRA corre-
lated with corresponding preinfusion PRA (r 0.72, P < 0.001).
PAldo and plasma sodium (138 I vs. 139 1 mEq/liter) were
not significantly changed following isoprenaline infusion, but
plasma potassium was slightly decreased (P < 0.05) (Table 3).
Effects of corticotropin. Before i.v. injection of alpha
24corticotropin (8 to 9 A.M.), plasma sodium in the diabetic
patients averaged 137 1 mEq/liter; potassium, 4 0.1
mEq/liter; PRA, 1.54 0.36 ng!ml/hr; plasma cortisol, 10.1
0.8 gIdl; and AIdO, 2.8 0.5 ngldl. After administration or
corticotropin, mean plasma cortisol was increased to 23.8 0.9
p.g/dl at 30 mm (P < 0.001) and to 28.1 1.3 pg/dl at 60 mm.
PAIdO was markedly increased at 30 mm following corticotropin
(to 16.8 1.3 ng/dl; P < 0.001) and not modified further at 60
mm (15.7 1.8 ng/dl).
A
10
5
0.5
0.2
0.1
0.1
Fig. 4. Relationship between basal (supine) and angiotensin II (All)-
suppressed plasma renin activity (PRA) in normal subjects and patients
with diabetes mellitus.
N r P
0.81 <0.001
0.90 <0.001
0.2 0.5 1 2
Supine PRA. ng/m//hr
5 10
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Table 3. Clinical and biochemical measurements before and during isoprenaline infusion in diabetic patients
Preinfusion
Isoprenaline infusion
After 12 mm After 25 mm
Blood pressure, ,nm Hg 125/73 4/2 140/66 4/3 143/64 4/3
Heart rate, beats/mm 67 2 88 3d 92 4d
Plasma potassium, mEq/!iter 4.21 0.11 — 3.91 0.09"
PRA, ng/m!/hr 1.17 0.3 2.01 0.43 2.74 0.59d
Plasma aldosterone, ng/dl 2.7 0.8 — 3.3 1.0
The target dose rate for isoprenaline was 16.3 2.4. Values given here are for the infusion at the final dose rate.
b p < 0.05, P < d P < 0.001 vs. corresponding preinfusion value.
Discussion
The renin-angiotensin-aldosterone system in our patients
with stable nonazotemic diabetes mellitus was characterized by
(1) diminished responsiveness of PRA and PAldo to the stimulus
of upright posture alone or in combination with i. v. furosemide;
(2) a distinct increase in PRA as induced by the beta adrenergic
receptor agonist isoprenaline; (3) a normal reduction in PRA in
response to exogenous AT! and (4) marked and seemingly
normal increases in PAldo and cortisol concentrations following
the administration of All or corticotropin. These data point to a
partial disturbance in PRA control systems, namely a defect in
the mechanism(s) of postural and furosemide-induced renin
release in the presence of functioning noradrenergic pathways
and beta receptors and intact All-mediated feedback inhibition.
Moreover, our observations suggest that two stimulatory path-
ways of aldosterone secretion, for example, adrenal All-recep-
tor activation and postreceptor ACTH-dependent biosynthesis
[25] may be intact in most nonazotemic patients with diabetes
mellitus.
A decrease in upright PRA has been noted previously in
diabetic patients with normal [3, 6] or impaired renal function
[1], with or without hypertension [1, 3] and especially with
orthostatic hypotension [2, 261. Posture and furosemide proba-
bly stimulate renin secretion through different mechanisms [27,
28]. The present protocol did not differentiate between the two
stimuli used alone. But, the blunted renin-responsiveness to
upright posture in our patients with nonazotemic diabetes
mellitus could not be fully accounted for by a renin-inhibiting
effect of aging [5, 24, 29], overhydration, hyperkalemia [30], or
disturbed adrenergic function [31, 32]. Thus, mean age, plasma
and urinary potassium and sodium, exchangeable body sodium,
and blood volume did not differ significantly between our
patients and normal control subjects. This does not exclude a
contributory role of excess body sodium in previously studied
populations of nonazotemic diabetics or diabetic patients with
terminal renal failure, in whom hypertension was much more
prevalent [3, 34, 35]. Although the dose rate of isoprenaline
used in the present study was slightly lower than that previously
infused into normal subjects [18, 33], the induced increases in
heart rate (+ 37%) and PRA (+ 134%) were quite comparable,
suggesting that cardiac and renin-regulating beta receptors were
sensitive in our nonazotemic diabetic patients. It is possible that
diminished sensitivity of renin-regulating beta receptors may
develop in the complicated phase of the disease and may
contribute to the pathogenesis of hyporeninemic hypoaldoste-
ronism [12]. The findings of generally normal plasma and
urinary norepinephrine levels in the present or previously
studied nonazotemic diabetic patients [3, 5] provided no evi-
dence of decreased sympathetic outflow. PE concentrations
tended to be low in the subgroup of our diabetic patients with
normal blood pressure, but renin responsiveness in these pa-
tients appeared to be only minimally impaired; whereas unal-
tered or even somewhat high (supine position) E values were
found in the subgroup of diabetics with mild hypertension
whose postural PRA responsiveness was more distinctly im-
paired. The greater degree of renin abnormality in the mildly
hypertensive subgroup is consistent with a contributory role of
elevated blood pressure. Nevertheless, disturbed renin regula-
tion in nonazotemic diabetes mellitus probably can not be fully
explained by coexistent hypertension, because our previous
analysis of a large diabetic population revealed mildly impaired
renin responsiveness also in patients with normal blood pres-
sure [5]. Blood glucose, which may be yet another factor with
the potential to modulate renin release [36], was comparable
between diabetic patients with low, normal, or high PRA [5].
Furosemide may stimulate renin release through sodium-
volume depletion [27, 28], an adrenergic-related mechanism
[37], a direct intrarenal vascular effect [38], and perhaps also by
activation of prostaglandins [39]. The former mechanism was
probably not responsible for the blunted PRA responsiveness to
furosemide in our patients. Thus, the furosemide-induced uri-
nary sodium excretion, under conditions of upright posture,
was of only mild degree, and values did not differ significantly
between our normal and diabetic subjects. Increases in NE
concentration following administration of furosemide were also
comparable between the two groups. But, a contributory role of
low blood levels of epinephrine to impaired renin responsive-
ness to furosemide in some of our diabetic patients can not be
excluded [40]. Our patients receiving furosemide were on
average only slightly older than the controls (50 vs. 39 years);
the modulatory effect of this small age range would appear to be
minimal [24].
Contrasting with the quantitative deficiency of upright and
furosemide-stimulated PRA, the qualitative dynamics of renin
release appeared to be intact in our diabetic patients. The
significant functional relationship between basal and upright or
furosemide-stimulated PRA that was noted in normal subjects
(P < 0.001) was also present in the diabetic patients (r = 0.45; P
<0.05), with a difference in slope only. Moreover, the normal
and diabetic subjects responded to pharmacologic pressor
doses of All with a similar suppression of circulating renin,
which in both groups was closely related to preinfusion PRA (r
= 0.81; P < 0.001) and was also weakly dose-dependent (r =
0.34; P < 0.01).
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This pattern of limited responsiveness with normal suppress-
ibility of PRA is consistent with a reduced functional reserve of
otherwise intact renin production sites. Arteriolar hyalinosis in
the juxtoglomerular area [13] could possibly underline such a
defect in nonazotemic diabetes mellitus, but an influence of
high systemic pressure [411, functional alterations of the renal
vasculature [42] or of the prostaglandin system [43] appear to be
attractive alternatives. In fact, the normal PRA response to
prolonged stimulation with the diuretic chlorthalidone [44] may
favor the participation of a functional disturbance. The ob-
served pattern of PRA in nonazotemic diabetes mellitus, partic-
ularly in patients with mild hypertension, is quite comparable to
that described by some authors in benign essential hypertension
[17, 45—47]. Therefore, considering the close clinical associa-
tion between the two diseases, a common mechanism leading to
altered renin release appears possible.
The tendency for impaired PAldo responses to upright posture
and furosemide in our diabetic patients was probably at least in
part related to the concomitant renin deficiency and, therefore,
of renal origin. But, the dissociation between the postural
responses of PRA and PAldo in some diabetic patients [3, 4]
raised the possibility of an additional mechanism of altered
aldosterone control. An inactive form of renin could play a role
[14]. Moreover, a primary defect of adrenal function has been
considered [3, 7, 8]. The present study revealed no evidence of
impaired adrenal responsiveness to Al! or ACTH. Aldosterone
responses to i.v. Al! were of comparable magnitude and
similarly related to basal PAldo levels in our normal and diabetic
subjects, despite a lower angiotensin-dose rate in the latter.
This could be consistent with an enhanced sensitivity of the
adrenal receptors to All, as noted previously in association
with low circulating renin levels in patients with essential
hypertension [4, 6, 49, 50] or normal subjects [17]. An alterna-
tive explanation for the diminished ratio between angiotensin
dose and PAldo response in the diabetic patients may be that the
pharmacologic All doses infused in the present study could
have induced already maximal aldosterone stimulation, cone-
sponding to the flat part of the dose-response curve. In fact, our
observation of comparable aldosterone responses in subgroups
of 15 normal and of 15 diabetic subjects receiving identical
doses of All may be consistent with the latter explanation. On
the other hand, aldosterone and cortisol responses to a fixed
dose of corticotropin (0.25 mg) were also quite comparable
between our diabetic patients and normal subjects studied
under similar conditions [19].
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